Press Release: Joslin Diabetes Center, Inc. : Phase 3 Trial Finds Oral Empagliflozin Provided Safe Glycemic Control in Children with Type 2 Diabetes

Researchers recently completed a phase 3 clinical trial that assessed the efficacy and safety of two different classes of oral agents for the treatment of type 2 diabetes in young people aged 10-17 years.